, Tracking Stock Market Picks
Enter Symbol:
Rating: AMED
Buy $49

Amedisys Inc (NASDAQ: AMED) upgraded to Buy with price target $49 by Mizuho

Tuesday,  Jan 19, 2016  8:25 AM ET by Lynn Gilbert

Mizuho upgraded Amedisys Inc (NASDAQ: AMED) to Buy with price target $49.
Previously, Mizuho rated Amedisys Inc (NASDAQ: AMED) to Neutral with price target $45 on 11/11/2015, when the stock price was valued at $42.02.

Amedisys, Inc. (Amedisys) is a provider of home health services to the chronic, co-morbid, aging American population. The services that the Company provides include both home health and hospice services with approximately 87% of its revenue derived from Medicare. As of December 31, 2008, Amedisys owned and operated 480 Medicare-certified home health agencies, 48 Medicare-certified hospice agencies and managed the operations of four Medicare-certified home health and two Medicare-certified hospice agencies in 37 states within the United States, the District of Columbia and Puerto Rico. Its home health patient is Medicare eligible, approximately years old and takes approximately 12 different medications on a daily basis and has multiple co-morbidities. For the Company?s home health patients, it receives a 60-day, episodic-based payment from Medicare. On March 26, 2008, the Company completed the acquisition of TLC Health Care Services, Inc.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy